Unveiling the Potential of Cmax f2 Factor Applied to Pilot Bioavailability/Bioequivalence Studies—A Case Study with Pazopanib Drug Products
Pharmaceutics · 11.12.2024 · 16 (12) · 1579
DOI: 10.3390/pharmaceutics16121579 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 11.12.2024. Verfasst von Sara Carolina Henriques und 6 weiteren Autor:innen. Beteiligte Einrichtung: BlueClinical Ltd., Senhora da Hora, 4460-439 Matosinhos, Portugal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bluepharma-Indústria Farmacêutica, S.A..
Abstract (Originalsprache)
Background
When companies are uncertain about the potential of a new formulation to be bioequivalent to a Reference product, it is common practice to carry out downsized pilot studies as a gatekeeping in vivo strategy to decide whether to move forward or not with a full-size pivotal study. However, due to the small study size, these studies are inarguably more sensitive to variability.
Objectives
To address and mitigate the uncertainty of the conclusions of pilot studies concerning the maximum observed concentration (Cmax), the f2 factor was proposed as an alternative approach to the average bioequivalence statistical methodology.
Methods
In this work, the alternative methodology is applied to pharmacokinetic data from pilot bioequivalence trials performed with pazopanib 200 mg and 400 mg.
Results
Despite the small sample size, and very high intra-subject variability, the f2 factor demonstrated the potential for predicting bioequivalence. The positive results were confirmed in the full sized pivotal studies.
Conclusions
In conclusion, this alternate methodology shows promise in reducing uncertainty associated with pilot studies and aiding in decisions to go forward with pivotal bioequivalence studies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- BlueClinical Ltd., Senhora da Hora, 4460-439 Matosinhos, Portugal.
- Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisbon, Portugal.
- Bluepharma-Indústria Farmacêutica, S.A., São Martinho do Bispo, 3045-016 Coimbra, Portugal.
- Faculty of Pharmacy, University of Coimbra, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal.
- Department of Biomedicine, Unit of Pharmacology & Therapeutics, Faculty of Medicine, University of Porto, 4200-450 Porto, Portugal.
- MedInUP-Center for Drug Discovery and Innovative Medicines, University of Porto, 4200-450 Porto, Portugal.
ORCID-Profile: Sara Carolina Henriques, Ana Leblanc, Sérgio Simões, Marlene Fonseca, Francisco Luís Pimentel, Luis Almeida, Nuno Elvas Silva
Förderung
- Bluepharma-Indústria Farmacêutica, S.A.
Zitieren
APA
Henriques, S. C., Leblanc, A., Simões, S., Fonseca, M., Pimentel, F. L., Almeida, L., & Silva, N. E. (2024). Unveiling the Potential of Cmax f2 Factor Applied to Pilot Bioavailability/Bioequivalence Studies—A Case Study with Pazopanib Drug Products. Pharmaceutics, 16(12), 1579. https://doi.org/10.3390/pharmaceutics16121579
Vancouver
Henriques SC, Leblanc A, Simões S, Fonseca M, Pimentel FL, Almeida L, et al. Unveiling the Potential of Cmax f2 Factor Applied to Pilot Bioavailability/Bioequivalence Studies—A Case Study with Pazopanib Drug Products. Pharmaceutics. 2024;16(12):1579. doi:10.3390/pharmaceutics16121579
BibTeX
@article{Henriques2024,
author = {Henriques, Sara Carolina and Leblanc, Ana and Simões, Sérgio and Fonseca, Marlene and Pimentel, Francisco Luís and Almeida, Luis and Silva, Nuno Elvas},
title = {Unveiling the Potential of Cmax f2 Factor Applied to Pilot Bioavailability/Bioequivalence Studies—A Case Study with Pazopanib Drug Products},
journal = {Pharmaceutics},
year = {2024},
volume = {16},
number = {12},
pages = {1579},
doi = {10.3390/pharmaceutics16121579}
}
EUVIMED